Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IST:ONCSM's EV-to-EBIT is ranked worse than 89.25% of 465
companies
in the Medical Devices & Instruments industry
Industry Median: 18.43
vs IST:ONCSM: 59.39
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Enterprise Value for the quarter that ended in Mar. 2026 was ₺6,122.4 Mil.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺115.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS EV-to-EBIT Related Terms
Oncosem Onkolojik Sistemlernayi ve Ticaret AS EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS EV-to-EBIT Chart
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS EV-to-EBIT vs Medical Devices & Instruments Industry
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current Enterprise Value is ₺6,873.7 Mil.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺115.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) has a EV-to-EBIT of 59.39 as of Jul. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. According to the industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #415 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 89.2%.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS's EV-to-EBIT too high?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current EV-to-EBIT is 59.39. The Medical Devices & Instruments industry median EV-to-EBIT is 18.43. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 59.39 is 222.2% above this industry median. Based on the distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #415 out of 465 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncosem Onkolojik Sistemlernayi ve Ticaret AS's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #415 out of 465 companies for EV-to-EBIT. This places Oncosem Onkolojik Sistemlernayi ve Ticaret AS in the lower half of its industry. The industry median EV-to-EBIT is 18.43. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 59.39 is 222.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.43, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current EV-to-EBIT of 59.39 is 222.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current EV-to-EBIT is 59.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) is currently considered Modestly Overvalued. The stock's GF Value™ is ₺255.12, compared to a current price of ₺284.00 — trading 11.3% above its estimated fair value. The current EV-to-EBIT is 59.39 and 222.2% above the Medical Devices & Instruments industry median of 18.43. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM), the current EV-to-EBIT is 59.39 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Overvalued in 2026?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺284.00 is trading 11.3% above its estimated GF Value™ of ₺255.12.
GuruFocus considers Oncosem Onkolojik Sistemlernayi ve Ticaret AS to be Modestly Overvalued.
Key valuation signals for IST:ONCSM:
EV-to-EBIT: 59.39
GF Value™: ₺255.12 vs. price of ₺284.00 (11.3% above fair value)
Industry Position: 222.2% above the Medical Devices & Instruments median (#415 of 465)
No single metric tells the full story. See the IST:ONCSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ONCSM has been successfully added to your 
